Biomedical, Clinical & Life Sciences

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limited Language
This is a limited submission opportunity: each institution may nominate ONE applicant for this funding opportunity 

Program Overview
At Susan G. Komen®, we are committed to saving lives by meeting the most critical needs in our communities and investing in breakthrough research to conquer deadly and aggressive breast cancers. We are determined to change the unacceptable reality that each year about 43,000 people in the U.S. will die from breast cancer. As part of this goal, we are focused on improving the care and outcomes for people with inflammatory breast cancer (IBC), a rare and highly aggressive form of breast cancer.  

IBC is characterized by tumor cell emboli blocking the breast lymph vessels. This blockage causes inflammatory-like changes in the breast, including swelling and skin reddening. The American Joint Committee on Cancer (AJCC) guidelines define IBC by the rapid onset (less than 6 months) of erythema occupying at least 1/3 of the breast, edema, peau d’ orange (orange peel-like appearance) and/or warmth (with or without an underlying mass), and pathologic confirmation of invasive carcinoma. Although IBC has been recognized as a distinct form of breast cancer for over a century, its etiology and underlying biological mechanisms remain poorly understood. Consequently, no validated, widely adopted IBC-specific biomarkers or targeted therapies exist, and current management is largely informed by evidence from non-IBC breast cancer. This limited understanding of IBC biology remains a significant barrier to the development of more precise diagnostic and therapeutic approaches, highlighting the need for research focused on the unique mechanisms driving the disease. Therefore, the goal of the Inflammatory Breast Cancer (IBC) Research Grant is to support innovative, hypothesis-driven research that advances our understanding of the biological underpinnings of IBC and opens new avenues of investigation into the disease.  

To identify areas where investment could have the greatest impact, the Susan G. Komen-IBCRF IBC Collaborative, in partnership with the Milburn Foundation, convened the Biology of IBC Task Force, a group of IBC researchers and patient advocates. The Task Force identified three broad areas of scientific opportunity that require significant investigation to advance the field: 

• 1. IBC onset and development, including studies focused on the tumor and host microenvironment, epigenetic and proteomic drivers of disease, host genetic factors and biological contributors to health disparities. 

  2. IBC metastatic dissemination, including mechanisms of cell migration and mobility, biological characteristics associated with therapeutic response and the role of tumor and host, epigenetic and proteomic factors in IBC disease progression. 

  3. IBC monitoring and detection, including approaches to detect minimal residual disease (MRD), improve prognostication, assess therapeutic response and advance theragnostic strategies. 

Eligibility 
Applicant/PIs and Institutions must conform to the following eligibility criteria to apply for an Inflammatory Breast Cancer Research Grant. Grants will be awarded to a single Principal Investigator (PI). Co-Principal Investigators (Co-PIs) are not allowed. CoInvestigators are permitted. 
Applicant/PI 

• Must be nominated as the sole Applicant/PI from their institution by the Institution’s Office of Sponsored Programs, Grants Office, or equivalent. This is a limited submission opportunity, and the Applicant/PI cannot self-nominate.  
• Must have a doctoral degree, such as M.D., Ph.D., D.Ph., D.O. or equivalent. 
• Must hold a full-time faculty appointment or have a formal offer letter from the Institution that confirms position and start date by the Full Application due date (January 18, 2027), documented by the Applicant/PI Biosketch.  
• May NOT be the PI of an active Komen Grant that includes specific aims or objectives focused on IBC at the Full Application due date (January 18, 2027).  
• May NOT be the PI of two or more active Komen Grants at the Full Application due date (January 18, 2027) 
• Must ensure that all past Komen-funded Grants are up to date and in compliance with all Komen requirements, e.g., progress and financial report submissions, IRB approvals, etc. by the Full Application due date (January 18, 2027), if applicable. 
• Is not required to be a U.S. citizen or permanent resident. 
• The institution-nominated Applicant/PI may submit only one Letter of Intent in response to this funding announcement.  

Institutionally Coordinated // Limit: 3* 

For additional information, please contact Marie Teemant. 

Limiting Language
Each institution may submit up to three nominations, one in each disciplinary category of Life Sciences, Physical Sciences & Engineering, and Chemical Sciences.

Program Overview
The Blavatnik National Awards for Young Scientists recognize the United States' most promising faculty-rank researchers in Life Sciences, Physical Sciences & Engineering, and Chemical Sciences. One Blavatnik National Awards Laureate in each disciplinary category will receive $250,000 in unrestricted funds, and additional nominees will be recognized as Finalists, and will receive $15,000 in unrestricted funds.

Eligibility
The nominee must:

• Have been born in or after 1985*.
• Hold a doctorate degree (PhD, DPhil, MD, DDS, DVM, etc.).
• Currently hold a tenured or tenure-track academic faculty position, or equivalent, at an eligible institution in the United States.
• Currently conduct research as a principal investigator in one of the disciplinary categories in Life Sciences, Physical Sciences & Engineering, or Chemical Sciences.

Request Ticket // Limit: 3 // Tickets Available: 3

Limiting Language
A maximum of three RGP applications will be accepted from one institution in any one grant cycle; it is the responsibility of the Lead Applicant and the host institution to coordinate the number of applications submitted. Institutions are encouraged to contact us to discuss the prioritisation of their applications, if needed. The INSPIRE Research Challenge is delivered as a separate grant call, so you are welcome to make another three applications as an institution to this.

Research Priority Areas
To focus this expanded programme where it can have the greatest impact, our 2026-27 grant calls will include six priority areas, identified through evidence gaps highlighted by the Global Cancer Update Programme, our strategic objectives and consultation with our scientific stakeholders.

For the 2026-27 grant call, applications must focus on at least one of the six priority areas. Applications may span more than one priority area where this is scientifically justified; applicants should identify all relevant areas and make the main alignment of the proposed research clear.  Alignment with a priority area does not replace the usual requirements for scientific quality, relevance to WCRF International’s remit, feasibility and potential impact. For this year’s grant call, sleep will be included as a primary exposure alongside diet, nutrition, physical activity and body composition.

1. Integrative Oncology
2. Lifestyle and weight-loss medications
3. Early-onset cancers
4. Early-life exposures
5. Ingested contaminants
6. Ultra-processed foods

Request Ticket // Limit: 3 // Tickets Available: 3

Limiting Language
A maximum of three applications will be accepted from one institution in any one grant cycle; it is the responsibility of the Lead Applicant and the lead institution to coordinate the number of applications submitted. Institutions are encouraged to contact us to discuss the prioritisation of their applications, if needed. The Regular Grant Programme has a separate limit of three applications per institution per grant cycle.

Priority Research Areas
To focus this expanded programme where it can have the greatest impact, our 2026-27 grant calls will include six priority areas, identified through evidence gaps highlighted by the Global Cancer Update Programme, our strategic objectives and consultation with our scientific stakeholders.

For the 2026-27 grant call, applications must focus on at least one of the six priority areas. Applications may span more than one priority area where this is scientifically justified; applicants should identify all relevant areas and make the main alignment of the proposed research clear.  Alignment with a priority area does not replace the usual requirements for scientific quality, relevance to WCRF International’s remit, feasibility and potential impact. 

1. Integrative Oncology
2. Lifestyle and weight-loss medications
3. Early-onset cancers
4. Early-life exposures
5. Ingested contaminants
6. Ultra-processed foods

Eligibility
The programme is open to early career researchers – defined as individuals who are within 2–7 years full-time equivalent working in research since the award date of their PhD or equivalent higher research degree.

Eligible applicants must be employed on a research contract within a department at a university-affiliated research institution or a medical school conducting research.

Proposed projects must have direct relevance to cancer prevention, treatment or survivorship and may address any or all stages of the cancer journey.

Proposals should address modifiable factors including diet, nutrition, body composition, physical activity, sleep, psychological stress, immune function, ingested contaminants and pathogens.

Request Ticket // Limit: One Proposal per Division (topic and implementation sites must be distinct)

M. Fain (Center on Aging - COM-T)

Limiting Language
Only one LOI may be submitted per organization unless they come from separate divisions and are addressing distinct topics with non-overlapping implementation sites.

Overview
The John A. Hartford Foundation (JAHF) is entering a new chapter that builds on its work to improve care for older adults and support family caregivers while bringing new organizations, leaders and ideas into its community of grantees and partners.

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution is allowed, as defined in Section III. 3. Additional Information on Eligibility. 

Please note, under Section III. 3, it states, "Applicant organizations may submit more than one application, provided that each application is scientifically distinct". NIH has clarified the first statement on limiting language, indicating a limit of one, is the correct one.

Purpose of Funding Opportunity
This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P&F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in new approaches, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. 

Apply to Internal Competition // Limit: 4 (one per program plus one additional possible for select research areas) // Tickets Available: 4
 

Limiting Language

Total submissions allowed per institution:one submission in each program category, plus one additional submission under the funding interest submission, if eligible. 

St. Baldrick’s Foundation has identified the areas below as funding interests and has donors interested in supporting meritorious projects in these areas. To encourage submissions in these priority areas, institutions may submit one additional LOI beyond the standard limited submissions. Only one additional submission is permitted per institution for the entire cycle; this does not allow one additional submission in each program or funding category. 

• Rhabdomyosarcoma 
• Brain tumors –especially atypical teratoid/rhabdoid tumor (AT/RT), diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG), and glioblastoma (GBM) 
• Burkitt lymphoma – all types, especially sporadic 
• Rhabdoid tumors - Extrarenal 

Program Descriptions

Full sponsor guidelines are linked here. 

St. Baldrick's Scholars

• The three (3) year Scholar (Career Development) Award, with an option for two (2) additional years based on progress, is meant to help develop the independent research of highly qualified individuals still early in their careers. Recipients are called St. Baldrick's Scholars. Up to $110,000/year, three-year minimum.
• Scholar (Career Development) Award LOI instructions
• Scholar (Career Development) Award Guidelines

St. Baldrick's International Scholars

• This three (3) year award, with an option for two (2) additional years based on progress, is to train researchers from low-and middle-income countries (as classified by the World Bank) to prepare them to fill specific stated needs in an area of childhood cancer research upon returning to their country of origin. Recipients are called St. Baldrick's International Scholars. Up to $110,000/year, three-year minimum.
• International Scholar LOI instructions
• International Scholar Award Guidelines

Survivorship and Supportive Care Research Grant

• These grants are for specific one-year research projects which are hypothesis-driven and focus on areas related to survivorship and supportive care of children and adolescents with cancer. Examples include but are not limited to: studies related to the burden of morbidity, cause-specific mortality, understanding the pathogenesis of treatment-related complications, patient-reported outcomes or quality of life, health communication, health promotion, and psychosocial support across the trajectory from diagnosis to survivorship or end-of-life care.
• Survivorship and Supportive Care Research Grant LOI instructions
• Survivorship and Supportive Care Research Grant Guidelines

Request Ticket // Limit: 2 // Tickets Available: 1

J. Schwartz (Pharmacology)

Limiting Language 
Submissions will be evaluated to ensure they align with our mission and funding criteria. A limit of two proposals may be submitted from the same institution, researcher, or foundation.

Program Overview
SebastianStrong Foundation is a 501c3 nonprofit organization dedicated to raising awareness of childhood cancer and accelerating the development of more targeted, less toxic treatments by funding bold, early-stage research. Since 2017, we have awarded over $4 million to cutting-edge, peer-reviewed pediatric cancer research. Through strategic partnerships, matched contributions, and follow-on funding secured by investigators, our overall impact now exceeds $6 million.
 

We exist because kids deserve better. Too many promising ideas in pediatric cancer research go unfunded due to limited institutional support, lack of commercial incentive, and minimal government investment, especially for rare and relapsed cancers. At SebastianStrong, we focus exclusively on childhood cancers, where small patient populations often mean traditional funders and pharmaceutical companies overlook research.

ABOUT THE DISCOVERY SCIENCE AWARD

The Discovery Science Award typically provides up to $500,000 in funding for groundbreaking research that aligns with our mission. In select cases, proposals demonstrating exceptional potential for impact and scalability may be considered for higher levels of support.

Our Scientific Advisory Board, composed of leading pediatric oncologists and researchers, conducts a two-stage review process. First, Letters of Intent (LOIs) are evaluated to identify projects that best align with our mission and funding priorities. Selected applicants are then invited to submit a full proposal, which is reviewed in detail to determine final award decisions. Funding recommendations are made by the Scientific Advisory Board and approved by the Foundation’s Board of Directors.

To be considered for funding, proposals must meet the following criteria:

1. Are focused on pediatric cancer
2. Will lead to less toxic, more targeted treatments
3. Are clearly communicated in lay terms (accessible to our Board and donor community)
4. Demonstrate strong potential to progress toward a clinical trial in 1-3 years

We welcome new, ongoing, and updated peer-reviewed research. However, we do not accept in-progress or ongoing clinical trials. Any author or researcher conflict of interest must be disclosed at the time of submission. All submissions are treated as CONFIDENTIAL and are accessible only to members of SebastianStrong’s Board of Directors and Scientific Advisory Board until the time of award. We are happy to execute NDAs upon request.

WHAT WE’RE LOOKING FOR

SebastianStrong funds one or more proposals each year that advance meaningful change in pediatric cancer treatment. We are especially interested in research that:

• Focuses on pediatric cancers with low survival rates or high relapse rates
• Has transitional potential within 36 months
• Pursues underfunded or unconventional approaches that could change the status quo

Limit: Each research center may appear on one LOI/Proposal

G. Coronado (Health Equity Research Center)

Limiting Language
Centers may be included in only one application. Duplicate applications will be marked as ineligible.

Purpose
Through this CFP, RWJF will expand its efforts to transform deeply rooted beliefs about which data and research methods are valued, whose perspectives are prioritized, and which populations deserve resources. This CFP works to achieve transformation by incorporating a holistic funding approach that focuses on the infrastructure and capacity support that research centers need to meaningfully engage in research in the first place. RWJF understands that no single philanthropy can completely fill the gap left by ongoing federal funding cuts; however, this CFP demonstrates strong support for research, researchers, and research centers that are well positioned to pave the way toward a future where health is not a privilege, but a right.  

RWJF believes in health equity research that is grounded in systems thinking; supports and disseminates evidence identifying and implementing structural solutions to racial and health inequities; and increases power, representation, and agency among historically underrepresented researchers. By supporting the infrastructure and capacity-building needs of MSIs, this opportunity strengthens their ability to generate critical evidence and to cultivate transformative, actionable solutions toward health equity.  

This CFP seeks mission-aligned institutions interested in participating in cohort-style peer learning to advance their ability to engage in health equity research and apply for competitive funding opportunities in the future.  

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Applicants are only allowed to submit one proposal per organization. If more than one proposal is submitted from an organization, all proposals from that institution will be considered ineligible for funding.

Executive Summary
The Bureau of Emerging Threats (ET) leads the Department of State in anticipating and responding to national security challenges arising from adversary use of new technologies across cyberspace, outer space, critical infrastructure and undersea domains, quantum technologies, and artificial intelligence (AI). ET focuses on protecting U.S. national security in these areas of strategic and technological competition using diplomatic tools and interagency capabilities as part of coordinated foreign policy responses.

Within ET, the Office of Critical Infrastructure Security (ET/CI) is responsible for addressing novel threats and disruptions to critical infrastructure that threaten lives, economic stability, and national power. ET/CI addresses threat vectors targeting major critical infrastructure sectors, including energy systems, communications networks, transportation and logistics, financial systems, healthcare, and water, and works to coordinate “upgrade and secure” efforts with allies and partners, counter attacks against data centers, and protect against cloud security vulnerabilities.

In the Western Hemisphere, adversaries have exploited weak cyber defenses in government networks and critical infrastructure to gain intelligence advantages, potential coercive leverage over sovereign decision-making, and latent access pathways that may extend to U.S. interests. Argentina, under the Milei administration, has signaled that it seeks close alignment with the United States on strategic and economic issues, including a deliberate transition away from untrusted foreign digital infrastructure suppliers in favor of trusted, market-oriented partners.

Persistent and sophisticated cyber threats—including advanced persistent threats (APTs), targeted ransomware, and espionage campaigns—continue to target Argentine ministries and critical infrastructure. Without a mature national-level Security Operations Center (SOC) with clear authorities, mission, charter, and well-trained staff, a country’s ability to detect, analyze, and respond to such threats in a coordinated manner remains limited.